Results 181 to 190 of about 12,403 (234)

Biologic Therapies in Severe Asthma and Eosinophilic Granulomatosis with Polyangiitis: Targeted Therapy and Personalized Care. [PDF]

Tuberc Respir Dis (Seoul)
Kim SH.
europepmc   +1 more source

Eosinophilic Granulomatosis with Polyangiitis (EGPA) without History of Asthma [PDF]

Aronin, Ryan G., Sun, Frank
core  

Some of the next articles are maybe not open access.

Related searches:

Eosinophilic granulomatosis with polyangiitis

Medicina Clínica (English Edition), 2023
Eosinophilic granulomatosis with polyangiitis (EGPA) is a systemic vasculitis characterized by the presence of asthma associated with eosinophilia, eosinophilic infiltration of different organs, and vasculitis of small and medium-sized vessels. Although classified as anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, it occurs in less ...
Yann Nguyen, Loïc Guillevin
  +7 more sources

Dupilumab for relapsing or refractory sinonasal and/or asthma manifestations in eosinophilic granulomatosis with polyangiitis: a European retrospective study

Annals of the Rheumatic Diseases, 2023
Background Eosinophilic granulomatosis with polyangiitis (EGPA) is often associated with glucocorticoid-dependent asthma and/or ear, nose and throat (ENT) manifestations.
Berengere Molina, R. Padoan, M. L. Urban, Pavel Novikov, M. Caminati, C. Taillé, Antoine Néel, L. Bouillet, P. Fraticelli, N. Schleinitz, C. Christides, Laura Moi, Bertrand Godeau, A. Knight, J. Schroeder, Sylvain Marchand-Adam, Helder Gil, V. Cottin, C. Durel, E. Gelain, B. Lerais, M. Ruivard, M. Groh, M. Samson, L. Moroni, J. Thiel, A. Kernder, J. C. Cohen Tervaert, G. Costanzo, M. Folci, S. Rizzello, P. Cohen, G. Emmi, B. Terrier   +33 more
semanticscholar   +1 more source

Targeting Eosinophils in Eosinophilic Granulomatosis with Polyangiitis

New England Journal of Medicine, 2017
Eosinophilic granulomatosis with polyangiitis, first described in the early 1950s by Dr. Jacob Churg and Dr. Lotte Strauss (hence the original name, the Churg–Strauss syndrome), is a rare condition that can affect many organ systems, most commonly the lung, with the majority of patients presenting with asthma symptoms, occasionally complicated by the ...
Djukanović, Ratko, O'Byrne, Paul
openaire   +2 more sources

Biologics for eosinophilic granulomatosis with polyangiitis

Current Opinion in Allergy & Clinical Immunology, 2022
Purpose of review The link between severe asthma and eosinophilic granulomatosis with polyangiitis (EGPA) in terms of pathophysiological background, clinical manifestations and disease evolution has leaded to investigate the relevance of anti T2 monoclonal antibodies licensed for severe asthma patients as a treatment option for
Caminati, Marco, Maule, Matteo, Bello, Federica, Emmi, Giacomo   +3 more
openaire   +4 more sources

Benralizumab for eosinophilic granulomatosis with polyangiitis: a retrospective, multicentre, cohort study.

The Lancet Rheumatology, 2023
BACKGROUND Interleukin-5 (IL-5) inhibitors represent novel therapies for eosinophilic granulomatosis with polyangiitis (EGPA). This study assessed the effectiveness and safety of the IL-5 receptor inhibitor benralizumab in a European cohort of patients ...
A. Bettiol, M. Urban, R. Padoan, Matthieu Groh, G. Lopalco, A. Egan, V. Cottin, P. Fraticelli, C. Crimi, S. Del Giacco, L. Losappio, Laura Moi, F. Cinetto, M. Caminati, Pavel Novikov, A. Berti, P. Cameli, P. Cathébras, A. Coppola, C. Durel, M. Folci, A. L. Gullo, C. Lombardi, S. Monti, P. Parronchi, Carlos Martinez Rivera, R. Solans, Angelo Vacca, G. Espígol-Frigolé, G. Guarnieri, F. C. Bianchi, M. R. Marchi, C. Tcherakian, Jean-Emmanuel Kahn, F. Iannone, V. Venerito, C. Desaintjean, Gianluca Moroncini, S. Nolasco, G. Costanzo, J. Schroeder, C. Ribi, M. Tesi, E. Gelain, I. Mattioli, F. Bello, David R W Jayne, Domenico Prisco, Augusto Vaglio, G. Emmi   +49 more
semanticscholar   +1 more source

Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis.

New England Journal of Medicine
BACKGROUND Eosinophilic granulomatosis with polyangiitis (EGPA) is a vasculitis characterized by eosinophilic inflammation. Benralizumab, a monoclonal antibody against the interleukin-5α receptor expressed on eosinophils, may be an option for treating ...
Michael E. Wechsler, P. Nair, B. Terrier, Bastian Walz, A. Bourdin, D. Jayne, D. J. Jackson, F. Roufosse, L. Börjesson Sjö, Ying Fan, M. Jison, C. Mccrae, S. Necander, A. Shavit, C. Walton, Peter A. Merkel   +15 more
semanticscholar   +1 more source